| Title |
A randomized clinical trial of unfractioned heparin for treatment of sepsis (the HETRASE study): design and rationale [NCT00100308]
|
|---|---|
| Published in |
Trials, May 2006
|
| DOI | 10.1186/1745-6215-7-19 |
| Pubmed ID | |
| Authors |
Fabián Jaimes, Gisela De La Rosa, Clara Arango, Fernando Fortich, Carlos Morales, Daniel Aguirre, Pablo Patiño |
| Abstract |
Infection promotes coagulation via a large number of molecular and cellular mechanisms, and this procoagulant activity has boosted basic and clinical research using anticoagulant molecules as therapeutic tools in sepsis. Heparin, which is a naturally occurring proteoglycan that acts by reducing thrombin generation and fibrin formation, has not been rigorously tested in a randomized clinical trial. |
Mendeley readers
The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 36 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Professor | 6 | 17% |
| Student > Master | 4 | 11% |
| Researcher | 3 | 8% |
| Student > Ph. D. Student | 3 | 8% |
| Student > Bachelor | 2 | 6% |
| Other | 10 | 28% |
| Unknown | 8 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 42% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
| Nursing and Health Professions | 2 | 6% |
| Psychology | 2 | 6% |
| Business, Management and Accounting | 1 | 3% |
| Other | 5 | 14% |
| Unknown | 9 | 25% |